IPHA
Innate Pharma
NASDAQ: IPHA · HEALTHCARE · BIOTECHNOLOGY
$1.36
-4.47% today
Updated 2026-06-05
Market cap
$170.90M
P/E ratio
—
P/S ratio
18.98x
EPS (TTM)
$-0.64
Dividend yield
—
52W range
$1 – $3
Volume
0.1M
WallStSmart proprietary scores
11
out of 100
Grade: F
Strong Sell
Investment rating
2.0
Growth
F5.0
Quality
C+2.5
Profitability
F5.0
Valuation
C+2/9
Piotroski F-Score
Weak
-12.1
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$6.00
+341.18%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
0 Strong Buy3 Buy1 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Debt/equity -1.04x — low leverage
Risks
- Piotroski 2/9 — weak financial health
- Altman Z -12.05 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-23.48M
- Revenue declining -46.70% QoQ
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $57.67M | $51.90M | $12.62M | $2.79M | $9.01M |
| Net income | $-58.10M | $-7.57M | $-49.47M | $-49.18M | $-27.63M |
| EPS | — | — | — | — | $-0.64 |
| Free cash flow | $-20.28M | $-34.91M | $-7.29M | $-50.81M | $-23.48M |
| Profit margin | -100.74% | -14.59% | -391.97% | -1,764.51% | — |
Peer comparison
Smart narrative
Innate Pharma trades at $1.36. Our Smart Value Score of 11/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of -12.05, it sits in the distress. TTM revenue stands at $9.01M.
Frequently asked questions
What is Innate Pharma's stock price?
Innate Pharma (IPHA) trades at $1.36, on a P/S of 19.0x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Innate Pharma overvalued?
Innate Pharma carries a Smart Value Score of 11/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Innate Pharma (IPHA)?
The 12-month analyst consensus target is $6.00, about 341.2% above the current $1.36. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is Innate Pharma's revenue?
Innate Pharma's trailing twelve-month revenue is $9.01M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Innate Pharma's Altman Z-Score is -12.05, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio18.98x
ROE-271.40%
Beta0.81
50D MA$1.55
200D MA$1.79
Shares out0.09B
Float0.07B
Short ratio—
Avg volume0.1M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—